Severina Leu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Severina Leu has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
Luigi Mariani
Department of Neurosurgery, University Hospital of Basel, Spitalstrasse 21, Basel, 4031, Switzerland
9 shared publicationsJehuda Soleman
Department of Neurosurgery, University Hospital of Basel, Spitalstrasse 21, Basel, 4031, Switzerland
5 shared publications- Jean-Louis Boulay
Department of Biomedicine, University Hospital Basel and University of Basel, Hebelstrasse 20, 4031 Basel, Switzerland
4 shared publications Stephan Frank
Department of Neuropathology, University Hospital Basel, Basel, Switzerland
4 shared publicationsFlorian Samuel Halbeisen
Surgical Outcome Research Center Basel, University Hospital of Basel, Basel, Switzerland
3 shared publicationsJean-Louis Boulay
Brain Tumor Immuno-Therapy and Biology Laboratory, Department of Biomedicine, University Hospital of Basel, University of Basel, Hebelstrasse 20, Basel 4031, Switzerland
3 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (9) , 3566-3570
From shunt to gut: managing a ventriculoperitoneal shunt–associated abdominal pseudocyst causing bowel obstruction – a case report
Introduction and importance: Abdominal cerebrospinal fluid pseudocysts (APCs) are a rare complication of ventriculoperitoneal (VP) shunts, occurring in 1–4.5% of cases and potentially causing abdominal symptoms, bowel obstruction, or shunt malfunction. We present a case of a VP shunt–associated pseudocyst leading to mechanical small bowel obstruction. Presentation of case: A 40-year-old woman with a long-standing VP shunt presented with abdominal pain, vomiting, and obstipation. CT imaging showed a large pseudocyst encasing the shunt tip and causing mechanical ileus. Emergency surgery revealed adhesion-related small-bowel obstruction, requiring partial cystectomy and ileal resection. cerebrospinal fluid (CSF) cultures grew Cutibacterium acnes , prompting complete shunt removal, external ventricular drainage, and later placement of a ventriculoatrial shunt. She recovered with conservative management of minor postoperative complications. Clinical discussion: APCs may form due to impaired CSF absorption, inflammation, or low-grade infection. In this patient, a chronic shunt infection likely contributed to cyst development and bowel obstruction. Management typically requires cyst drainage or resection, and revision of the distal catheter, with complete shunt removal necessary when infection is present. Early diagnosis and multidisciplinary management are essential to prevent morbidity. Conclusion: VP shunt–associated pseudocysts, though rare, can cause acute abdominal emergencies. Prompt imaging, surgical intervention, and appropriate treatment of shunt infection are critical for optimal outcomes.
- 5 August 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (9) , 3566-3570
Open AccessFrom shunt to gut: managing a ventriculoperitoneal shunt–associated abdominal pseudocyst causing bowel obstruction – a case report
Introduction and importance: Abdominal cerebrospinal fluid pseudocysts (APCs) are a rare complication of ventriculoperitoneal (VP) shunts, occurring in 1–4.5% of cases and potentially causing abdominal symptoms, bowel obstruction, or shunt malfunction. We present a case of a VP shunt–associated pseudocyst leading to mechanical small bowel obstruction. Presentation of case: A 40-year-old woman with a long-standing VP shunt presented with abdominal pain, vomiting, and obstipation. CT imaging showed a large pseudocyst encasing the shunt tip and causing mechanical ileus. Emergency surgery revealed adhesion-related small-bowel obstruction, requiring partial cystectomy and ileal resection. cerebrospinal fluid (CSF) cultures grew Cutibacterium acnes , prompting complete shunt removal, external ventricular drainage, and later placement of a ventriculoatrial shunt. She recovered with conservative management of minor postoperative complications. Clinical discussion: APCs may form due to impaired CSF absorption, inflammation, or low-grade infection. In this patient, a chronic shunt infection likely contributed to cyst development and bowel obstruction. Management typically requires cyst drainage or resection, and revision of the distal catheter, with complete shunt removal necessary when infection is present. Early diagnosis and multidisciplinary management are essential to prevent morbidity. Conclusion: VP shunt–associated pseudocysts, though rare, can cause acute abdominal emergencies. Prompt imaging, surgical intervention, and appropriate treatment of shunt infection are critical for optimal outcomes.
- Open Access
- 26 June 2026
- Published by Springer Nature in Fluids and Barriers of the CNS
- Vol. 23 (1)
Ultrasound-guided versus stereotactically navigated ventriculoperitoneal shunt placement: a randomized clinical trial
Background: Accurate catheter positioning is essential for optimal outcomes in ventriculoperitoneal shunt (VPS) surgery, while shorter operative times lower infection risk and costs. Navigated VPS placement, using either intraoperative ultrasound-guided (US-G) or stereotactically guided (ST-G) navigation, enhances catheter accuracy and reduces revision rates. However, high-quality studies comparing the two navigation methods are lacking. We aim to compare surgical intervention time, accuracy, and safety of US-G to ST-G VPS placement. Methods: The Navigated VPS (NAVPS) trial was an investigator-initiated, randomized trial conducted from February 2020 to June 2024 in the Neurosurgical Department of the University Hospital of Basel. Consecutive adults undergoing VPS placement were included. Out of 153 screened participants, 134 participants were included. Participants were randomized 1:1 to receive either US-G or ST-G insertion of the ventricular catheter. The primary outcome was surgical intervention time. An intention to treat analysis was performed calculating surgical intervention time differences. Secondary outcomes were accuracy of catheter positioning, number of ventricular puncture attempts, and VPS dysfunction and complication rates. The study follow-up lasted 6 months. Results: Of 134 participants, 66 were assigned to US-G and 68 to ST-G. The mean (SD) age was 73 (55.3 to 78) and 66 (54.5 to 73) years for the US-G and ST-G, respectively, and 58 participants (45.7%) were female. The US-G group had significantly shorter surgical intervention times compared to the ST-G group (-11.5 min; 95% CI -18.5 to -4.5; P = 0.002). The number of ventricular puncture attempts was significantly higher in the US-G group, while accuracy of catheter placement, and VPS dysfunction and complications rates were comparable in both groups. Conclusions: The NAVPS trial shows US-G VPS placement to be more time-efficient, while accuracy of catheter placement and complication rates seem to be comparable to ST-G placement. US-G can be efficiently and safely used in clinical practice. Trial registration: clinicalTrials.gov Identifier: NCT04450797, date of registration: 22.06.2020.
- 26 June 2026
- Published by Springer Nature in Fluids and Barriers of the CNS
- Vol. 23 (1)
Open AccessUltrasound-guided versus stereotactically navigated ventriculoperitoneal shunt placement: a randomized clinical trial
Background: Accurate catheter positioning is essential for optimal outcomes in ventriculoperitoneal shunt (VPS) surgery, while shorter operative times lower infection risk and costs. Navigated VPS placement, using either intraoperative ultrasound-guided (US-G) or stereotactically guided (ST-G) navigation, enhances catheter accuracy and reduces revision rates. However, high-quality studies comparing the two navigation methods are lacking. We aim to compare surgical intervention time, accuracy, and safety of US-G to ST-G VPS placement. Methods: The Navigated VPS (NAVPS) trial was an investigator-initiated, randomized trial conducted from February 2020 to June 2024 in the Neurosurgical Department of the University Hospital of Basel. Consecutive adults undergoing VPS placement were included. Out of 153 screened participants, 134 participants were included. Participants were randomized 1:1 to receive either US-G or ST-G insertion of the ventricular catheter. The primary outcome was surgical intervention time. An intention to treat analysis was performed calculating surgical intervention time differences. Secondary outcomes were accuracy of catheter positioning, number of ventricular puncture attempts, and VPS dysfunction and complication rates. The study follow-up lasted 6 months. Results: Of 134 participants, 66 were assigned to US-G and 68 to ST-G. The mean (SD) age was 73 (55.3 to 78) and 66 (54.5 to 73) years for the US-G and ST-G, respectively, and 58 participants (45.7%) were female. The US-G group had significantly shorter surgical intervention times compared to the ST-G group (-11.5 min; 95% CI -18.5 to -4.5; P = 0.002). The number of ventricular puncture attempts was significantly higher in the US-G group, while accuracy of catheter placement, and VPS dysfunction and complications rates were comparable in both groups. Conclusions: The NAVPS trial shows US-G VPS placement to be more time-efficient, while accuracy of catheter placement and complication rates seem to be comparable to ST-G placement. US-G can be efficiently and safely used in clinical practice. Trial registration: clinicalTrials.gov Identifier: NCT04450797, date of registration: 22.06.2020.
- Open Access
- 16 June 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (7) , 3610-3624
Quantitative Proteomic Analysis Reveals Different Functional Subtypes among IDH-Wildtype Glioblastoma
Purpose: Proteomics of glioma have not yet provided biomarkers and pathways that would clearly discriminate glioma subgroups. Methods: 82 glioma biopsies were prospectively collected and classified into six subgroups defined by methylomic classification: two low-grade glioma (LGG) and four high-grade glioma (HGG) subgroups. Proteins were extracted and processed for liquid chromatography-mass spectrometry (LC-MS). Differentially expressed proteins (DEPs) between subgroups were annotated, and functional validation was performed using inhibitor response assays in subtype-positive, patient-derived glioblastoma single-cell suspensions. Results: 5057 proteins were quantified for each sample. Tumor grading and IDH mutation status were the strongest discriminators for differential expression patterns. The glioblastoma IDH-wildtype subgroups showed diverse patterns of functions enriched with overexpressed DEPs: translation and cell cycle/telomere regulation in proneural glioblastoma (linked to cell proliferation), actin cytoskeleton, cell adhesion, and apoptosis regulation in classical glioblastoma (migration and invasion), and mitochondrial ATP synthesis in mesenchymal glioblastoma (metabolism). The most overexpressed proteins were correlated with survival and mRNA expression data. In vitro, inhibition of these proteins led to reduced cell viability that differed among subgroups, albeit in a small patient-derived exploratory cohort. Conclusion: This mainly descriptive study on proteomics in glioma provides insights into subgroup metabolism and potential biomarkers for further experimental testing.
- 16 June 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (7) , 3610-3624
Open AccessQuantitative Proteomic Analysis Reveals Different Functional Subtypes among IDH-Wildtype Glioblastoma
Purpose: Proteomics of glioma have not yet provided biomarkers and pathways that would clearly discriminate glioma subgroups. Methods: 82 glioma biopsies were prospectively collected and classified into six subgroups defined by methylomic classification: two low-grade glioma (LGG) and four high-grade glioma (HGG) subgroups. Proteins were extracted and processed for liquid chromatography-mass spectrometry (LC-MS). Differentially expressed proteins (DEPs) between subgroups were annotated, and functional validation was performed using inhibitor response assays in subtype-positive, patient-derived glioblastoma single-cell suspensions. Results: 5057 proteins were quantified for each sample. Tumor grading and IDH mutation status were the strongest discriminators for differential expression patterns. The glioblastoma IDH-wildtype subgroups showed diverse patterns of functions enriched with overexpressed DEPs: translation and cell cycle/telomere regulation in proneural glioblastoma (linked to cell proliferation), actin cytoskeleton, cell adhesion, and apoptosis regulation in classical glioblastoma (migration and invasion), and mitochondrial ATP synthesis in mesenchymal glioblastoma (metabolism). The most overexpressed proteins were correlated with survival and mRNA expression data. In vitro, inhibition of these proteins led to reduced cell viability that differed among subgroups, albeit in a small patient-derived exploratory cohort. Conclusion: This mainly descriptive study on proteomics in glioma provides insights into subgroup metabolism and potential biomarkers for further experimental testing.
- Open Access
- 16 June 2025
- Published by Elsevier in World Neurosurgery
- Vol. 200, 124167
Hydrocephalus in Surgically Treated Glioblastoma Patients – To Treat or Not to Treat?
- 16 June 2025
- Published by Elsevier in World Neurosurgery
- Vol. 200, 124167
Open AccessHydrocephalus in Surgically Treated Glioblastoma Patients – To Treat or Not to Treat?
- Open Access
- 24 May 2025
- Published by Elsevier in Journal Of Neuroradiology
- Vol. 52 (4) , 101354
Differentiation of tumor progression from pseudoprogression in glioblastoma patients with GRASP DCE-MRI and DSC-MRI
- 24 May 2025
- Published by Elsevier in Journal Of Neuroradiology
- Vol. 52 (4) , 101354
Open AccessDifferentiation of tumor progression from pseudoprogression in glioblastoma patients with GRASP DCE-MRI and DSC-MRI
- Open Access
Quantitative proteomic analysis reveals different functional subtypes among IDH-wildtype glioblastoma
Background: Proteomics of glioma have not yet provided biomarkers and pathways that would clearly discriminate glioma subgroups. Methods: 82 glioma biopsies were prospectively collected and classified into six subgroups defined by methylomic classification: two Isocitrate dehydrogenase (IDH)- mutated low-grade (LGG) and four high-grade glioma (HGG) subgroups: IDH- mutated HGG ( IDH HGG), proneural (GB PN), classical (GB CL), and mesenchymal glioblastoma (GB MES). Proteins were extracted and processed for liquid chromatography mass spectrometry (LC-MS). Differentially expressed proteins (DEPs) between subgroups were annotated using Gene Ontology (GO) function analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway analysis, and Protein-protein interaction (PPI). Functional validation was performed using inhibitor response assays in subtyped, non-cultured patient derived GB single cell suspensions. Results: 5057 proteins were quantified for each sample. Tumor grading and IDH mutation status were the strongest discriminators for differential expression patterns. The IDH -wildtype GB subgroups showed diverse patterns of pathways and functions enriched with overexpressed DEP (compared to LGG): Translation and cell cycle/telomere regulation in GB PN (linked to cell proliferation), actin cytoskeleton, cell adhesion and apoptosis regulation in GB CL (linked to migration and invasion), and mitochondrial ATP synthesis in GB MES (linked to metabolism). The most overexpressed and underexpressed proteins were correlated with survival and mRNA expression data. In vitro , inhibition of those proteins led to reduced cell viability that differed among subgroups, albeit in a small patient-derived exploratory cohort. Conclusion: This mainly descriptive study on proteomics in glioma provides insights into subgroup metabolism, and potential biomarkers for further experimental testing.
Open AccessQuantitative proteomic analysis reveals different functional subtypes among IDH-wildtype glioblastoma
Background: Proteomics of glioma have not yet provided biomarkers and pathways that would clearly discriminate glioma subgroups. Methods: 82 glioma biopsies were prospectively collected and classified into six subgroups defined by methylomic classification: two Isocitrate dehydrogenase (IDH)- mutated low-grade (LGG) and four high-grade glioma (HGG) subgroups: IDH- mutated HGG ( IDH HGG), proneural (GB PN), classical (GB CL), and mesenchymal glioblastoma (GB MES). Proteins were extracted and processed for liquid chromatography mass spectrometry (LC-MS). Differentially expressed proteins (DEPs) between subgroups were annotated using Gene Ontology (GO) function analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway analysis, and Protein-protein interaction (PPI). Functional validation was performed using inhibitor response assays in subtyped, non-cultured patient derived GB single cell suspensions. Results: 5057 proteins were quantified for each sample. Tumor grading and IDH mutation status were the strongest discriminators for differential expression patterns. The IDH -wildtype GB subgroups showed diverse patterns of pathways and functions enriched with overexpressed DEP (compared to LGG): Translation and cell cycle/telomere regulation in GB PN (linked to cell proliferation), actin cytoskeleton, cell adhesion and apoptosis regulation in GB CL (linked to migration and invasion), and mitochondrial ATP synthesis in GB MES (linked to metabolism). The most overexpressed and underexpressed proteins were correlated with survival and mRNA expression data. In vitro , inhibition of those proteins led to reduced cell viability that differed among subgroups, albeit in a small patient-derived exploratory cohort. Conclusion: This mainly descriptive study on proteomics in glioma provides insights into subgroup metabolism, and potential biomarkers for further experimental testing.
- Open Access
- 28 December 2022
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 165 (1) , 15-25
A prospective study of shared decision-making in brain tumor surgery
Purpose: Shared decision-making (SDM) is a key tenet of personalized care and is becoming an essential component of informed consent in an increasing number of countries. The aim of this study is to analyze patient and healthcare staff satisfaction with the SDM process before and after SDM was officially introduced as the standard of care. Decision grids are important tools in the SDM process, and we developed them for three different types of intracranial tumors. Methods: This prospective study was conducted in a high-volume neuro-oncological center on all consecutive eligible patients undergoing consideration of treatment for intracranial glioma and metastases. Twenty-two patients participated before and 74 after the introduction of SDM. Six and 5 staff members respectively participated in the analysis before and after team training and the introduction of SDM. The main outcome was patient and healthcare staff satisfaction with the SDM process. Results: Patients reported high satisfaction with the SDM process before (mean CollaboRATE score 26 of 27 points) and after (mean CollaboRATE score 26.3 of 27 points, p = 0.23) the introduction of SDM. Interestingly, staff attitude toward SDM improved significantly from 61.68 before to 90.95% after the introduction of SDM (p-value < 0.001). Decision grids that were developed for three different types of intracranial tumors are presented. Conclusions: Team training in SDM and the introduction of techniques into daily practice can increase staff satisfaction with the SDM process. High levels of patient satisfaction were observed before, with a non-significant increase after the introduction of SDM. Decision grids are an important tool to facilitate the conveyance and understanding of complex information and to achieve SDM in daily clinical practice.
- 28 December 2022
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 165 (1) , 15-25
Open AccessA prospective study of shared decision-making in brain tumor surgery
Purpose: Shared decision-making (SDM) is a key tenet of personalized care and is becoming an essential component of informed consent in an increasing number of countries. The aim of this study is to analyze patient and healthcare staff satisfaction with the SDM process before and after SDM was officially introduced as the standard of care. Decision grids are important tools in the SDM process, and we developed them for three different types of intracranial tumors. Methods: This prospective study was conducted in a high-volume neuro-oncological center on all consecutive eligible patients undergoing consideration of treatment for intracranial glioma and metastases. Twenty-two patients participated before and 74 after the introduction of SDM. Six and 5 staff members respectively participated in the analysis before and after team training and the introduction of SDM. The main outcome was patient and healthcare staff satisfaction with the SDM process. Results: Patients reported high satisfaction with the SDM process before (mean CollaboRATE score 26 of 27 points) and after (mean CollaboRATE score 26.3 of 27 points, p = 0.23) the introduction of SDM. Interestingly, staff attitude toward SDM improved significantly from 61.68 before to 90.95% after the introduction of SDM (p-value < 0.001). Decision grids that were developed for three different types of intracranial tumors are presented. Conclusions: Team training in SDM and the introduction of techniques into daily practice can increase staff satisfaction with the SDM process. High levels of patient satisfaction were observed before, with a non-significant increase after the introduction of SDM. Decision grids are an important tool to facilitate the conveyance and understanding of complex information and to achieve SDM in daily clinical practice.
- Open Access
- 1 November 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 24 (Supplement) , vii26
CNSC-20. PROTEOMIC ANALYSIS OF GLIOMA BIOPSIES SHOWS CONSISTENCY WITH GLIOMA GRADING
Glioma are currently classified according to integrated histopathologic and molecular genetic (WHO 2021 classification) as well as methylomic criteria (Capper 2018). However, little is known about proteomic profiling of these subgroups , which may reveal specific biomarkers and pathways potentially activated or inactivated. Material and Eighty-six glioma biopsy samples were prospectively collected from patients undergoing surgery at the University Hospital of Basel between 2017 and 2019. Samples were classified into seven distinct glioma subgroups based on integrated WHO 2016 and methylome profiling criteria. Proteins were extracted from fresh frozen samples devoid of necrosis/haemorrhage and processed for mass spectrometry analysis. For each tumour sample, a total of 8’855 proteins were identified and quantified. 950 proteins were differentially expressed between at least two glioma subgroups. Strikingly, most significant differences in expression are related to tumor grading rather than to glioma subgroups. Proteins SSDH and GABT, involved in Gamma-aminobutyric acid (GABA) catabolism, show the strongest increase between low grade glioma (LGG) and high grade glioma (HGG), whereas S10AA and ANXA2, part of pathways involved in coagulation, cell adhesion and immune response, appear increased in HGG. Tumor grading turns out to be dominant over genetic and epigenetic criteria for proteomic classification. Most significant protein level variations may represent potential glioma grade-specific therapeutic targets.
- 1 November 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 24 (Supplement) , vii26
Open AccessCNSC-20. PROTEOMIC ANALYSIS OF GLIOMA BIOPSIES SHOWS CONSISTENCY WITH GLIOMA GRADING
Glioma are currently classified according to integrated histopathologic and molecular genetic (WHO 2021 classification) as well as methylomic criteria (Capper 2018). However, little is known about proteomic profiling of these subgroups , which may reveal specific biomarkers and pathways potentially activated or inactivated. Material and Eighty-six glioma biopsy samples were prospectively collected from patients undergoing surgery at the University Hospital of Basel between 2017 and 2019. Samples were classified into seven distinct glioma subgroups based on integrated WHO 2016 and methylome profiling criteria. Proteins were extracted from fresh frozen samples devoid of necrosis/haemorrhage and processed for mass spectrometry analysis. For each tumour sample, a total of 8’855 proteins were identified and quantified. 950 proteins were differentially expressed between at least two glioma subgroups. Strikingly, most significant differences in expression are related to tumor grading rather than to glioma subgroups. Proteins SSDH and GABT, involved in Gamma-aminobutyric acid (GABA) catabolism, show the strongest increase between low grade glioma (LGG) and high grade glioma (HGG), whereas S10AA and ANXA2, part of pathways involved in coagulation, cell adhesion and immune response, appear increased in HGG. Tumor grading turns out to be dominant over genetic and epigenetic criteria for proteomic classification. Most significant protein level variations may represent potential glioma grade-specific therapeutic targets.
- Top Cited PapersOpen Access
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (34) , 3839-3852
Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated
PURPOSE: Meningiomas are the most frequent primary intracranial tumors. Patient outcome varies widely from benign to highly aggressive, ultimately fatal courses. Reliable identification of risk of progression for individual patients is of pivotal importance. However, only biomarkers for highly aggressive tumors are established ( CDKN2A/B and TERT), whereas no molecularly based stratification exists for the broad spectrum of patients with low- and intermediate-risk meningioma.METHODS: DNA methylation data and copy-number information were generated for 3,031 meningiomas (2,868 patients), and mutation data for 858 samples. DNA methylation subgroups, copy-number variations (CNVs), mutations, and WHO grading were analyzed. Prediction power for outcome was assessed in a retrospective cohort of 514 patients, validated on a retrospective cohort of 184, and on a prospective cohort of 287 multicenter cases.RESULTS: Both CNV- and methylation family–based subgrouping independently resulted in increased prediction accuracy of risk of recurrence compared with the WHO classification (c-indexes WHO 2016, CNV, and methylation family 0.699, 0.706, and 0.721, respectively). Merging all risk stratification approaches into an integrated molecular-morphologic score resulted in further substantial increase in accuracy (c-index 0.744). This integrated score consistently provided superior accuracy in all three cohorts, significantly outperforming WHO grading (c-index difference P = .005). Besides the overall stratification advantage, the integrated score separates more precisely for risk of progression at the diagnostically challenging interface of WHO grade 1 and grade 2 tumors (hazard ratio 4.34 [2.48-7.57] and 3.34 [1.28-8.72] retrospective and prospective validation cohorts, respectively).CONCLUSION: Merging these layers of histologic and molecular data into an integrated, three-tiered score significantly improves the precision in meningioma stratification. Implementation into diagnostic routine informs clinical decision making for patients with meningioma on the basis of robust outcome prediction.
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (34) , 3839-3852
Top Cited PapersOpen AccessIntegrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated
PURPOSE: Meningiomas are the most frequent primary intracranial tumors. Patient outcome varies widely from benign to highly aggressive, ultimately fatal courses. Reliable identification of risk of progression for individual patients is of pivotal importance. However, only biomarkers for highly aggressive tumors are established ( CDKN2A/B and TERT), whereas no molecularly based stratification exists for the broad spectrum of patients with low- and intermediate-risk meningioma.METHODS: DNA methylation data and copy-number information were generated for 3,031 meningiomas (2,868 patients), and mutation data for 858 samples. DNA methylation subgroups, copy-number variations (CNVs), mutations, and WHO grading were analyzed. Prediction power for outcome was assessed in a retrospective cohort of 514 patients, validated on a retrospective cohort of 184, and on a prospective cohort of 287 multicenter cases.RESULTS: Both CNV- and methylation family–based subgrouping independently resulted in increased prediction accuracy of risk of recurrence compared with the WHO classification (c-indexes WHO 2016, CNV, and methylation family 0.699, 0.706, and 0.721, respectively). Merging all risk stratification approaches into an integrated molecular-morphologic score resulted in further substantial increase in accuracy (c-index 0.744). This integrated score consistently provided superior accuracy in all three cohorts, significantly outperforming WHO grading (c-index difference P = .005). Besides the overall stratification advantage, the integrated score separates more precisely for risk of progression at the diagnostically challenging interface of WHO grade 1 and grade 2 tumors (hazard ratio 4.34 [2.48-7.57] and 3.34 [1.28-8.72] retrospective and prospective validation cohorts, respectively).CONCLUSION: Merging these layers of histologic and molecular data into an integrated, three-tiered score significantly improves the precision in meningioma stratification. Implementation into diagnostic routine informs clinical decision making for patients with meningioma on the basis of robust outcome prediction.
- Open Access
- 19 May 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-12
Intraoperative ultrasound-guided compared to stereotactic navigated ventriculoperitoneal shunt placement: study protocol for a randomised controlled study
Background: Ventriculoperitoneal shunt (VPS) placement is one of the most frequent neurosurgical procedures and the operation is performed in a highly standardised manner under maintenance of highest infection precautions. Short operation times are important since longer duration of surgery can increase the risk for VPS complications, especially infections. The position of the proximal ventricular catheter influences shunt functioning and survival. With freehand placement, rates of malpositioned VPS are still high. Several navigation techniques for improvement of shunt placement have been developed. Studies comparing these techniques are sparse. The aim of this study is to prospectively compare ultrasound (US) guided to stereotactic navigated shunt placement using optical tracking with the focus on operation time and efficiency. Methods: In this prospective randomised, single-centre, partially-blinded study, we will include all patients undergoing VPS placement in our clinic. The patients will be randomised into two groups, one group undergoing US-guided (US-G) and the other group stereotactic navigated VPS placement using optical tracking. The primary outcome will be the surgical intervention time. This time span consists of the surgical preparation time together with the operation time and is given in minutes. Secondary outcomes will be accuracy of catheter positioning, VPS dysfunction and need for revision surgery, total operation and anaesthesia times, and amount of intraoperative ventricular puncture attempts as well as complications, any morbidity and mortality. Discussion: To date, there is no prospective data available comparing these two navigation techniques. A randomised controlled study is urgently needed in order to provide class I evidence for the best possible surgical technique of this frequent surgery. Trial registration: Business Administration System for Ethical Committees (BASEC) 2019-02157, registered on 21 November 2019, https://www.kofam.ch/de/studienportal/suche/88135/studie/49552; clinicalTrials.gov: NCT04450797, registered on 30 June 2020.
- 19 May 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-12
Open AccessIntraoperative ultrasound-guided compared to stereotactic navigated ventriculoperitoneal shunt placement: study protocol for a randomised controlled study
Background: Ventriculoperitoneal shunt (VPS) placement is one of the most frequent neurosurgical procedures and the operation is performed in a highly standardised manner under maintenance of highest infection precautions. Short operation times are important since longer duration of surgery can increase the risk for VPS complications, especially infections. The position of the proximal ventricular catheter influences shunt functioning and survival. With freehand placement, rates of malpositioned VPS are still high. Several navigation techniques for improvement of shunt placement have been developed. Studies comparing these techniques are sparse. The aim of this study is to prospectively compare ultrasound (US) guided to stereotactic navigated shunt placement using optical tracking with the focus on operation time and efficiency. Methods: In this prospective randomised, single-centre, partially-blinded study, we will include all patients undergoing VPS placement in our clinic. The patients will be randomised into two groups, one group undergoing US-guided (US-G) and the other group stereotactic navigated VPS placement using optical tracking. The primary outcome will be the surgical intervention time. This time span consists of the surgical preparation time together with the operation time and is given in minutes. Secondary outcomes will be accuracy of catheter positioning, VPS dysfunction and need for revision surgery, total operation and anaesthesia times, and amount of intraoperative ventricular puncture attempts as well as complications, any morbidity and mortality. Discussion: To date, there is no prospective data available comparing these two navigation techniques. A randomised controlled study is urgently needed in order to provide class I evidence for the best possible surgical technique of this frequent surgery. Trial registration: Business Administration System for Ethical Committees (BASEC) 2019-02157, registered on 21 November 2019, https://www.kofam.ch/de/studienportal/suche/88135/studie/49552; clinicalTrials.gov: NCT04450797, registered on 30 June 2020.